A patient’s transition from “living” to “dying” is not socially marked in the same way death is marked, and this is both clinically and ethically relevant.
AMA J Ethics. 2020;22(12):E1062-1066. doi:
10.1001/amajethics.2020.1062.
Dania Pagarkar joins Ethics Talk to discuss her article, coauthored with Drs Erin Harrop and Lisa Erlanger: “How Should We Approach Body Size Diversity in Clinical Trials?”